Dexa Medica Group

What Dexa Medica Group does

Dexa Medica Group, founded in 1969 in Palembang, South Sumatera by Letkol CKM (Purn.) apt. Drs. Rudy Soetikno, is one of Indonesia's largest privately held pharmaceutical companies. It is headquartered in Tangerang and operates as a vertically integrated manufacturer spanning three specialized factories — PT Dexa Medica Palembang (solid and cephalosporin production), PT Dexa Medica Cikarang (active pharmaceutical ingredient production, discovery, research and development), and PT Beta Pharmacon Karawang (high-volume solid production) — with combined annual output exceeding 1 billion tablets, vials and ampoules. Its research footprint includes the Dexa Development Center (DDC), an integrated facility in Jababeka, Cikarang designed for up to 250 scientists and up to 30 CTD/ACTD dossiers per year, and Dexa Laboratories of Biomolecular Sciences (DLBS), operational since 2005, which discovers active ingredients indigenous to Indonesia from plants, animals and microbes for use in standardized herbal medicines and phytopharmaca.

The company's product portfolio comprises branded generic pharmaceuticals, the OGBdexa line of non-branded generic medicines (Obat Generik Berlogo) with more than 187 SKUs, its Integrative Modern Natural Medicine (OMAI) range — covering 29 of 96 registered Standardized Herbal Medicines (OHT) and 24 of 29 registered phytopharmaca in Indonesia — and vitamins and supplements. Dexa holds Good Manufacturing Practices (CPOB) certification and is one of only five Indonesian companies authorized to produce OGB, having been the first private Indonesian producer of non-branded generics. Its go-to-market is sales-led: it operates across more than 80,000 pharmacies, hospitals, health offices and community health clinics (puskesmas) in Indonesia and supplies medicines into the JKN national health insurance system, which covers 282 million beneficiaries, with pricing subject to government regulation.

Name

Dexa Medica Group

Legal name

PT Dexa Medica

Website

https://dexa-medica.com

Company type

Private

Founded year

1969

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Dexa Medica Group is one of Indonesia's largest privately held pharmaceutical manufacturers, producing branded generics, non-branded generics (OGB), standardized herbal medicines and phytopharmaca across three factories and one research complex, distributing through 80,000+ healthcare points and Indonesia's JKN national health insurance system.

Ownership category

akta.pro rank

Product category

Pharmaceutical Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412), Medicinal and Botanical Manufacturing (325411), Drugs and Druggists' Sundries Merchant Wholesalers (42421), Scientific Research and Development Services (5417)

SIC

Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)

akta.pro primary industry

Generic Tender & Government Supply Markets (HLAIABAM)

akta.pro secondary industry

Government & Public-Sector Pharmaceutical Supply (Tender/Prime Vendor) (HLAIAJAF)

Keywords

• Generic pharmaceuticals
• Herbal medicines
• Pharmaceutical manufacturing
• Branded generics
• Biomolecular research

Headquarters

HQ city

Tangerang

HQ country

Indonesia

HQ region

Asia

Offices4 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Supply Chain, Personnel, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Branded Generic Pharmaceuticals: Sale of proprietary branded generic pharmaceutical products manufactured in-house, targeting healthcare providers and patients across Indonesia
2. Standardized Herbal Medicines (OHT) and Phytopharmaca: Production and sale of Integrative Modern Natural Medicine (OMAI) products including 29 of 96 registered OHT and 24 of 29 registered phytopharmaca in Indonesia
3. Obat Generik Berlogo (OGB) Non-branded Generics: Production of non-branded generic medicines as part of Indonesian national health insurance system (JKN), with portfolio of more than 187 medicines and production capacity of 1 billion+ tablets, vials, and ampoules annually

Go-to-market motion1 record

Distribution channels5 records

Marketing channels6 records

Core offering

Dexa Medica manufactures and distributes pharmaceutical products in Indonesia, including branded generics, non-branded generics (OGB/OGBdexa), standardized herbal medicines and phytopharmaca (OMAI), and vitamins and supplements. The company operates three manufacturing facilities, an integrated research facility (DDC), and a biomolecular sciences research wing (DLBS), and distributes products through 80,000+ healthcare points including participation in the national JKN health insurance program.

Product overview

Dexa Medica Group is a single-platform pharmaceutical company offering multiple product lines including Integrative Modern Natural Medicine (OMAI) with Standardized Herbal Medicines (OHT) and phytopharmaca, OGBdexa branded generics (187+ medicines portfolio), Branded Generic products, and Vitamins and Supplements. The company operates manufacturing facilities producing over 1 billion units annually and maintains research capabilities through the Dexa Development Center (DDC) and Dexa Laboratories of Biomolecular Sciences (DLBS).

Differentiator

Problem solved

Functional benefit

Brands

• OGBdexa: Obat Generik Berlogo (non-branded generics) product line with over 187 medicines portfolio
• Dexa Development Center (DDC)
• Dexa Laboratories of Biomolecular Sciences (DLBS)

Products and services

• Integrative Modern Natural Medicine (OMAI) Standardized Herbal Medicines (OHT) and phytopharmaca that have passed pre-clinical and clinical trials respectively, derived from Indonesian biodiversity; targeted at healthcare providers and patients seeking clinically tested herbal alternatives.
• OGBdexa (Obat Generik Berlogo) Non-branded generic medicines produced by Dexa Medica with a portfolio of more than 187 medicines and annual production capacity of 1 billion+ tablets, vials, and ampoules; supplied through Indonesia's national health insurance system JKN and other channels.
• Branded Generic Pharmaceuticals Proprietary branded generic pharmaceutical products manufactured and distributed by Dexa Medica for healthcare providers, hospitals, and pharmacies across Indonesia.
• Vitamins and Supplements Vitamins and dietary supplements offered by Dexa Medica Group to consumers through pharmacy and healthcare distribution channels.

Quantifiable outcome

• 29 of 96 registered OHT and 24 of 29 registered phytopharmaca produced by Dexa
• +3 more outcomes

Named customers4 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Two partnerships are on record, tiered core.

• Indonesian FarmerscoreStrategic or Co-development PartnerDexa Medica collaborates with and trains farmers to produce high-quality, standardized natural ingredients from Indonesian biodiversity. This partnership supports the DLBS initiative to discover active ingredients from indigenous Indonesian life sources including plants, animals, and microbes.
• Indonesian Healthcare InstitutionscoreStrategic or Co-development PartnerDexa Medica establishes strategic alliances with healthcare institutions as part of its core competencies. The company focuses on selecting and maintaining the right partners for synergistic improvements in healthcare delivery across Indonesia.

Scale indicators9 records

Recent moves7 records

Expansion highlights8 records

Regional players

• Pyridam Farma: Indonesia-based pharmaceutical manufacturer with generic, OTC, and herbal medicine portfolios. Comparable to Dexa on OMAI-style herbal offerings and JKN distribution.

Direct peers

• Kalbe Farma: Indonesia's largest pharmaceutical company, offering branded generics, consumer health, and distribution across an even larger footprint. Comparable to Dexa as a domestic ethical pharma leader with JKN participation and integrated manufacturing-distribution.
• Kimia Farma: State-owned Indonesian pharmaceutical manufacturer and pharmacy retailer with extensive government-supply and JKN exposure. Closely comparable to Dexa in business mix (generics + government + retail distribution).
• Indofarma: State-owned Indonesian pharmaceutical company focused on generics and JKN supply. Directly comparable to Dexa's OGB and tender-supply business, though smaller in scale.
• Tempo Scan Pacific: Listed Indonesian pharmaceutical and consumer healthcare group with branded generics and OTC portfolios. Comparable to Dexa on branded-generic manufacturing and broad domestic distribution.
• Sanbe Farma: Indonesian pharmaceutical manufacturer with broad generic and specialty pharma portfolios and multiple production facilities. Comparable vertically-integrated Indonesian pharma with similar product breadth.
• PHAPROS: Indonesian pharmaceutical company specializing in generics with strong government/INAMED supply presence. Comparable to Dexa on JKN/government tender participation.

Broad incumbents

• Sandoz (Novartis): Global leader in off-patent generics, including biosimilars. Comparable to Dexa as a generic manufacturer competing in Indonesia and adjacent Southeast Asia markets, albeit at vastly larger scale.
• Teva Pharmaceutical: One of the world's largest generic pharmaceutical manufacturers. Comparable to Dexa as a broad generic-pharma operator with global manufacturing scale, though commercially focused on developed markets.

Emerging players

• Sun Pharmaceutical Industries: Leading Indian generic manufacturer with significant emerging-market focus. Comparable to Dexa as an emerging-market generic exporter that could compete for Indonesian tender volumes.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/@DexaGroupOfficial
• Facebookfacebook.com/dexagroup
• LinkedInlinkedin.com/company/dexa-medica
• Instagraminstagram.com/dexagroupofficial

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Subsidiaries7 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Dexa Medica Group